IDEXX Laboratories Inc.

IDEXX Laboratories develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company operates primarily through three business segments: Companion Animal Group, which provides diagnostic and information management-based products and services for the veterinary market; Water Quality Products, which designs, develops, manufactures, and distributes products used in the detection of various microbiological parameters in water; and Livestock, Poultry and Dairy, which provides diagnostic products and services for livestock and poultry health.
  • TickerIDXX
  • ISINUS45168D1046
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States

IDEXX LABORATORIES sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of IDEXX LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date March 9, 2021, the closing price was USD 493.57 and its target price was estimated at USD 404.09.

Valens Research

Valens Equity Insights and Inflections - 2021 01 26

Current market expectations for EBAY are excessively pessimistic. Markets expect UAFRS-based (Uniform) ROA (ROA') to decline significantly going forward, even though ROA' has been remarkably stable since the company spun off the PayPal business in 2015. However, EBAY has robust economic moats in its core marketplace and successfully monetized its StubHub business at the optimal time and its classifieds businesses. It is the market leader with strong competitive advantages, which give reasons for it to sustain its strong returns going forward. Management alignment and confidence in recent call...

Valens Research

IDXX - Embedded Expectations Analysis - 2021 01 22

IDEXX Laboratories, Inc. (IDXX:USA) currently trades at a historical high relative to UAFRS-based (Uniform) earnings, with a 69.7x Uniform P/E. At these levels, the market has bullish expectations for the firm, and management is confident about their diagnostic testing growth, LPD revenue, and free cash flow conversion Specifically, management is confident they make the viewing of results convenient for customers, that the Companion Animal Group (CAG) Diagnostic growth premium to clinical visits expanded, and that their Livestock, Poultry and Dairy (LPD) results benefited from strong demand f...

MarketLine Department

Virbac Corporation - Strategy, SWOT and Corporate Finance Report

Summary Virbac Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Virbac Corporation (Virbac or 'the company'), a subsidiary of Virbac SA, manufactures and markets animal health and pet care products. The company provides pharmaceutical products in the areas of endo- and ecto-parasiticides, dermatology, dental care, antibiotics, behavioral health, endoc...

MarketLine Department

Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Henry Schein, Inc. (Henry Schein or 'the company') is a provider of healthcare products and services primarily to office-based dental and medical practitioners. The company offers consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceutica...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in eme...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Two concerns we have previously highlighted on our march to new highs have been (1) improved RS from defensive Sectors/Groups and (2) weak foreign equity markets. Defensive posturing and lack of global participation has had a dampening effect on risk sentiment in recent months. While questions remain, short-term developments highlighted below are encouraging and improve our already constructive outlook. • On cue, outperformance last week and yesterday from cyclical pockets of the market led the S&P 500 to new all-time highs while defensive Sectors lagged. Additionally, weakness in the US do...

Dave Nicoski ...
  • John Betz

Vermilion Int'l Compass: Global Equity Strategy

Big-picture technicals offer a compelling outlook for equities -- in the long-run. Despite arguably stretched trends, especially in the U.S. and EM, one indicator in particular keeps us optimistic: monthly charts. What is likely the least-used timeframe, monthly charts (> 20 years) offer the most clarity. And what's clear right now is: (1) Europe is on the doorstep of breaking above secular resistance; (2) Japan is breaking out above secular resistance; (3) and EM already has. Speaking of EM, we view this as the place to be, or overweight, in 2018. The EM/EAFE's 20-year chart (below) reveals ...

Valens Research

Valens Equity Insights and Inflections - 2021 01 26

Current market expectations for EBAY are excessively pessimistic. Markets expect UAFRS-based (Uniform) ROA (ROA') to decline significantly going forward, even though ROA' has been remarkably stable since the company spun off the PayPal business in 2015. However, EBAY has robust economic moats in its core marketplace and successfully monetized its StubHub business at the optimal time and its classifieds businesses. It is the market leader with strong competitive advantages, which give reasons for it to sustain its strong returns going forward. Management alignment and confidence in recent call...

Valens Research

IDXX - Embedded Expectations Analysis - 2021 01 22

IDEXX Laboratories, Inc. (IDXX:USA) currently trades at a historical high relative to UAFRS-based (Uniform) earnings, with a 69.7x Uniform P/E. At these levels, the market has bullish expectations for the firm, and management is confident about their diagnostic testing growth, LPD revenue, and free cash flow conversion Specifically, management is confident they make the viewing of results convenient for customers, that the Companion Animal Group (CAG) Diagnostic growth premium to clinical visits expanded, and that their Livestock, Poultry and Dairy (LPD) results benefited from strong demand f...

MarketLine Department

Virbac Corporation - Strategy, SWOT and Corporate Finance Report

Summary Virbac Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Virbac Corporation (Virbac or 'the company'), a subsidiary of Virbac SA, manufactures and markets animal health and pet care products. The company provides pharmaceutical products in the areas of endo- and ecto-parasiticides, dermatology, dental care, antibiotics, behavioral health, endoc...

MarketLine Department

Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Henry Schein, Inc. (Henry Schein or 'the company') is a provider of healthcare products and services primarily to office-based dental and medical practitioners. The company offers consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceutica...

MarketLine Department

Myriad Genetics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Myriad Genetics Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Myriad Genetics Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage....

IDEXX LABORATORIES sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of IDEXX LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date March 9, 2021, the closing price was USD 493.57 and its target price was estimated at USD 404.09.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch